Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety of TX200-TR101 for Preventing Kidney Transplant Rejection in Patients Receiving a Living Donor Transplant

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a treatment for people who have received a kidney transplant from a living donor. The main concern in such cases is preventing the body from rejecting the new kidney, a condition known as renal transplant rejection. The treatment being tested is called TX200-TR101, which is a type of cell therapy. This therapy involves using a special kind of cell called a Chimeric Antigen Receptor T Regulatory Cell, which is designed to help the body accept the new kidney.

The purpose of the study is to evaluate the safety and tolerability of TX200-TR101 in patients who have received a kidney transplant. Participants in the study will receive a single dose of this treatment through an infusion, which means it will be delivered directly into the bloodstream. The study will monitor participants for any side effects or reactions to the treatment over a period of time, starting from the day of the infusion and continuing for several weeks.

Throughout the study, researchers will keep track of any health changes in the participants, including any signs of the body rejecting the kidney or other health issues. The study aims to gather information on how well the treatment works in helping the body accept the new kidney and whether it is safe for use in patients. This information will help determine if TX200-TR101 could be a beneficial treatment option for kidney transplant recipients in the future.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will have already provided written informed consent, confirming understanding and agreement to participate in the trial.

    Eligibility criteria include being between 18 and 70 years old, having end-stage renal disease, and awaiting a kidney transplant from a living donor.

  2. Step 2

    Preparation for infusion

    Before the infusion of TX200-TR101, a solution for infusion administered intravenously, the participant will undergo necessary pre-infusion assessments to ensure safety and readiness for the procedure.

  3. Step 3

    Infusion of TX200-TR101

    The participant will receive a single dose of TX200-TR101 through an intravenous infusion. This is a specialized cell therapy designed to help prevent kidney transplant rejection.

  4. Step 4

    Post-infusion monitoring

    For 28 days following the infusion, the participant will be closely monitored to evaluate the short-term safety and tolerability of the treatment.

    Monitoring will include checking for any adverse effects and ensuring the participant's well-being.

  5. Step 5

    Long-term follow-up

    The participant will continue to be monitored up to Week 84 to assess the incidence of transplant rejection and any other health changes.

    Regular assessments will include checking for infections, monitoring kidney function, and evaluating the effectiveness of the treatment.

Who can join the trial?

7 criteria

  • Willing and able to provide written informed consent, which means agreeing to participate in the study after understanding all the details and risks involved.
  • Must be between 18 and 70 years old.
  • Have a diagnosis of **ESRD**, which stands for **End-Stage Renal Disease**, and currently waiting for a new kidney from a live donor.
  • Will receive only one organ, specifically a kidney.
  • Have a normal or not seriously abnormal **ECG**, which is a test that checks the heart's electrical activity, as determined by the study doctor.
  • Women who can have children must have a negative pregnancy test at the start of the study and before the kidney transplant.
  • Must be able and willing to use a very effective method of birth control from the time of agreeing to participate in the study until the last study visit, for both men and women who can have children.

Who cannot join the trial?

3 criteria

  • Patients who are not within the specified age range for the study.
  • Patients who are not eligible based on gender requirements.
  • Patients who are considered part of a vulnerable population, which means they might be at higher risk of harm or exploitation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

TX200-TR101 is a type of cell therapy used in this clinical trial. It involves using a patient's own cells, which are modified to help regulate the immune system. This therapy is specifically designed for patients who have received a kidney transplant from a living donor. The goal of TX200-TR101 is to improve the body's acceptance of the new kidney by reducing the immune response that can lead to rejection. This trial aims to assess how safe and tolerable this therapy is for patients shortly after they receive it.

What is already known about the treatment

TX200-TR101 – This medication is administered as an infusion and is currently being studied in clinical trials for its safety and tolerability. It is designed to prevent rejection in patients who have received a kidney transplant from a living donor. The medication works by using genetically modified T regulatory cells that are specific to certain antigens, helping to regulate the immune response and prevent the body from attacking the transplanted organ. TX200-TR101 falls under the pharmacological classification of cell therapy, specifically involving chimeric antigen receptor T regulatory cells.

Investigated diseases

Renal Transplant Rejection – This condition occurs when the immune system of a person who has received a kidney transplant attacks the new kidney, mistaking it for a foreign object. The rejection can be acute, happening shortly after the transplant, or chronic, developing over a longer period. Symptoms may include decreased kidney function, pain or tenderness over the kidney, and changes in urine output. The immune response can lead to inflammation and damage to the transplanted kidney tissue. Over time, this can affect the kidney's ability to function properly. Monitoring and managing the immune response is crucial to maintaining the health of the transplanted kidney.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2024-512579-11-00Protocol codeTX200-KT02Estimated enrolment60 patientsSponsorSangamo Therapeutics France

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).